Literature DB >> 16596180

Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.

Jung-Il Lee1, Satoshi Itasaka, Ji Tae Kim, Do-Hyun Nam.   

Abstract

Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies. To overcome this problem, we investigated the combined effects of gamma knife radiosurgery (GKS) and an antiangiogenic agent, thalidomide (THD), or a chemotherapeutic agent, temozolomide (TMZ), on a rat glioma model. GKS (20 Gy single dose) alone and/or drugs (for 3 days) were delivered 14 or 18 days after stereotactic implantation of C6/LacZ glioma cells into the brains of Sprague-Dawley rats. A group of animals treated with or without drugs for 3 days was irradiated on day 18 and sacrificed at 24 h after GKS to evaluate cell proliferation, apoptosis and microvessel density. The other group of animals was irradiated on day 14 and sacrificed at day 5 after GKS for the measurement of tumor volume. Apoptosis of endothelial cells in the tumor beds was only observed in the early period after GKS. Decreased cell proliferation and increased tumor cell apoptosis were observed in rat gliomas treated with GKS and THD or TMZ. The combination treatments with GKS and THD or GKS and TMZ also decreased microvessel density, i.e. angiogenesis, more effectively compared with GKS treatment alone. The combination of GKS and THD was the most effective regimen, resulting in a significant decrease of tumor volume. We suggest that the antitumor effect of GKS on glioma is enhanced by the addition of THD. Therefore, combined therapy with GKS and THD might be a favorable treatment for gliomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596180

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Gamma knife radiosurgery treatment planning for small animals using high-resolution 7T micro-magnetic resonance imaging.

Authors:  D Wiant; T F Atwood; J Olson; M Papagikos; M E Forbes; D R Riddle; J D Bourland
Journal:  Radiat Res       Date:  2009-11       Impact factor: 2.841

Review 2.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

3.  Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide.

Authors:  Po-Chin Liang; Hui-Ju Ch'ang; Chiun Hsu; Li-Tzong Chen; Tiffany T F Shih; Tsang Wu Liu
Journal:  Hepatol Int       Date:  2014-07-26       Impact factor: 6.047

4.  Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.

Authors:  Olaf Penack; Erik Henke; David Suh; Chris G King; Odette M Smith; Il-Kang Na; Amanda M Holland; Arnab Ghosh; Sydney X Lu; Robert R Jenq; Chen Liu; George F Murphy; Theresa T Lu; Chad May; David A Scheinberg; Ding Cheng Gao; Vivek Mittal; Glenn Heller; Robert Benezra; Marcel R M van den Brink
Journal:  J Natl Cancer Inst       Date:  2010-05-12       Impact factor: 13.506

5.  Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model.

Authors:  A Nitta-Seko; N Nitta; A Sonoda; H Otani; K Tsuchiya; S Ohta; M Takahashi; K Murata
Journal:  Br J Radiol       Date:  2010-10-19       Impact factor: 3.039

Review 6.  Antiangiogenic therapy in brain tumors.

Authors:  Sajani S Lakka; Jasti S Rao
Journal:  Expert Rev Neurother       Date:  2008-10       Impact factor: 4.618

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.